Author:
Öcal Osman,Schütte Kerstin,Malfertheiner Peter,Berg Thomas,Loewe Christian,Klümpen Heinz Josef,Zech Christoph Johannes,van Delden Otto,Ümütlü Muzaffer Reha,Deniz Sinan,Khaled Najib Ben,De Toni Enrico Narciso,Hoang Thi Phuong Thao,Seidensticker Ricarda,Aghdassi Ali,Pech Maciej,Ricke Jens,Seidensticker Max
Subject
Radiology, Nuclear Medicine and imaging,General Medicine
Reference28 articles.
1. Clinical outcomes of radiofrequency ablation and surgical resection for small hepatocellular carcinoma: A meta-analysis;Li;J. Gastroenterol. Hepatol.,2012
2. EASL clinical practice guidelines: management of hepatocellular carcinoma;Liver;J. Hepatol.,2018
3. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial;Bruix;Lancet Oncol.,2015
4. M. Seidensticker, O. Öcal, K. Schütte, P. Malfertheiner, T. Berg, C. Loewe, H.J. Klümpen, O. van Delden, M.R. Ümütlü, N.B. Khaled, Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial, JHEP Reports (2023) 100699.
5. A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma at high risk of recurrence after curative hepatic resection or ablation: EMERALD-2;Knox;Ann. Oncol.,2019